StreetInsider.com News Articles

Appili Therapeutics to Exhibit at World Vaccine Congress Washington

Mon, 30 Mar 2026 07:19:00 -0400

Appili Presentation Highlights Recent Collaborations and Funding Milestones

Appili Executives to Conduct In-Person Meetings and in Washington, D.C. to Identify New Funding Opportunities

HALIFAX, Nova Scotia, March 30, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that President and Chief Executive Officer Dr. Don Cilla and Chief Development Officer, Dr. Gary Nabors will exhibit at the World Vaccine Congress Washington 2026.

“The World Vaccine Congress Washington provides an important

Appili Therapeutics to Exhibit at World Vaccine Congress Washington

Mon, 30 Mar 2026 07:19:00 -0400

Appili Presentation Highlights Recent Collaborations and Funding Milestones

Appili Executives to Conduct In-Person Meetings and in Washington, D.C. to Identify New Funding Opportunities

“The World Vaccine Congress Washington provides an important

Appili Therapeutics to Exhibit at World Vaccine Congress Washington

Mon, 30 Mar 2026 07:19:00 -0400

Appili Presentation Highlights Recent Collaborations and Funding Milestones

Appili Executives to Conduct In-Person Meetings and in Washington, D.C. to Identify New Funding Opportunities

“The World Vaccine Congress Washington provides an important

Appili Therapeutics to Exhibit at World Vaccine Congress Washington

Mon, 30 Mar 2026 07:19:00 -0400

Appili Presentation Highlights Recent Collaborations and Funding Milestones

Appili Executives to Conduct In-Person Meetings and in Washington, D.C. to Identify New Funding Opportunities

“The World Vaccine Congress Washington provides an important

Appili Therapeutics to Exhibit at World Vaccine Congress Washington

Mon, 30 Mar 2026 07:19:00 -0400

Appili Presentation Highlights Recent Collaborations and Funding Milestones

Appili Executives to Conduct In-Person Meetings and in Washington, D.C. to Identify New Funding Opportunities

“The World Vaccine Congress Washington provides an important

Appili Therapeutics to Exhibit at World Vaccine Congress Washington

Mon, 30 Mar 2026 07:19:00 -0400

Appili Presentation Highlights Recent Collaborations and Funding Milestones

Appili Executives to Conduct In-Person Meetings and in Washington, D.C. to Identify New Funding Opportunities

“The World Vaccine Congress Washington provides an important

Appili Therapeutics to Exhibit at World Vaccine Congress Washington

Mon, 30 Mar 2026 07:19:00 -0400

Appili Presentation Highlights Recent Collaborations and Funding Milestones

Appili Executives to Conduct In-Person Meetings and in Washington, D.C. to Identify New Funding Opportunities

“The World Vaccine Congress Washington provides an important

Appili Therapeutics to Exhibit at World Vaccine Congress Washington

Mon, 30 Mar 2026 07:19:00 -0400

Appili Presentation Highlights Recent Collaborations and Funding Milestones

Appili Executives to Conduct In-Person Meetings and in Washington, D.C. to Identify New Funding Opportunities

“The World Vaccine Congress Washington provides an important

Appili Therapeutics to Exhibit at World Vaccine Congress Washington

Mon, 30 Mar 2026 07:19:00 -0400

Appili Presentation Highlights Recent Collaborations and Funding Milestones

Appili Executives to Conduct In-Person Meetings and in Washington, D.C. to Identify New Funding Opportunities

“The World Vaccine Congress Washington provides an important

Appili Therapeutics to Exhibit at World Vaccine Congress Washington

Mon, 30 Mar 2026 07:19:00 -0400

Appili Presentation Highlights Recent Collaborations and Funding Milestones

Appili Executives to Conduct In-Person Meetings and in Washington, D.C. to Identify New Funding Opportunities

“The World Vaccine Congress Washington provides an important

Appili Therapeutics to Exhibit at World Vaccine Congress Washington

Mon, 30 Mar 2026 07:19:00 -0400

Appili Presentation Highlights Recent Collaborations and Funding Milestones

Appili Executives to Conduct In-Person Meetings and in Washington, D.C. to Identify New Funding Opportunities

“The World Vaccine Congress Washington provides an important

Appili Therapeutics to Exhibit at World Vaccine Congress Washington

Mon, 30 Mar 2026 07:19:00 -0400

Appili Presentation Highlights Recent Collaborations and Funding Milestones

Appili Executives to Conduct In-Person Meetings and in Washington, D.C. to Identify New Funding Opportunities

“The World Vaccine Congress Washington provides an important

Appili Therapeutics to Exhibit at World Vaccine Congress Washington

Mon, 30 Mar 2026 07:19:00 -0400

Appili Presentation Highlights Recent Collaborations and Funding Milestones

Appili Executives to Conduct In-Person Meetings and in Washington, D.C. to Identify New Funding Opportunities

“The World Vaccine Congress Washington provides an important

Appili Therapeutics to Exhibit at World Vaccine Congress Washington

Mon, 30 Mar 2026 07:19:00 -0400

Appili Presentation Highlights Recent Collaborations and Funding Milestones

Appili Executives to Conduct In-Person Meetings and in Washington, D.C. to Identify New Funding Opportunities

“The World Vaccine Congress Washington provides an important

Appili Therapeutics to Exhibit at World Vaccine Congress Washington

Mon, 30 Mar 2026 07:19:00 -0400

Appili Presentation Highlights Recent Collaborations and Funding Milestones

Appili Executives to Conduct In-Person Meetings and in Washington, D.C. to Identify New Funding Opportunities

“The World Vaccine Congress Washington provides an important

Appili Therapeutics to Exhibit at World Vaccine Congress Washington

Mon, 30 Mar 2026 07:19:00 -0400

Appili Presentation Highlights Recent Collaborations and Funding Milestones

Appili Executives to Conduct In-Person Meetings and in Washington, D.C. to Identify New Funding Opportunities

“The World Vaccine Congress Washington provides an important

Appili Therapeutics to Exhibit at World Vaccine Congress Washington

Mon, 30 Mar 2026 07:19:00 -0400

Appili Presentation Highlights Recent Collaborations and Funding Milestones

Appili Executives to Conduct In-Person Meetings and in Washington, D.C. to Identify New Funding Opportunities

“The World Vaccine Congress Washington provides an important

Appili Therapeutics to Exhibit at World Vaccine Congress Washington

Mon, 30 Mar 2026 07:19:00 -0400

Appili Presentation Highlights Recent Collaborations and Funding Milestones

Appili Executives to Conduct In-Person Meetings and in Washington, D.C. to Identify New Funding Opportunities

“The World Vaccine Congress Washington provides an important

Appili Therapeutics closes C$100,000 private placement second tranche

Wed, 18 Feb 2026 07:19:40 -0400

Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) completed the second tranche of its non-brokered private placement, raising C$100,000 in gross proceeds, according to a company statement.

The Halifax-based biopharmaceutical company issued 4,000,000 units at C$0.025 per unit. Each unit consists of one Class A common share and half of one common share purchase warrant. The warrants, subject to shareholder approval, allow holders to purchase one common share at C$0.05 for 36 months from the closing date.

The Toronto Stock Exchange requires shareholder approval for the warrants before they become exercisable. The company will seek this approval no later than its next Annual

Appili Therapeutics closes C$100,000 private placement second tranche

Wed, 18 Feb 2026 07:19:40 -0400

Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) completed the second tranche of its non-brokered private placement, raising C$100,000 in gross proceeds, according to a company statement.

The Toronto Stock Exchange requires shareholder approval for the warrants before they become exercisable. The company will seek this approval no later than its next Annual

Appili Therapeutics closes C$100,000 private placement second tranche

Wed, 18 Feb 2026 07:19:40 -0400

Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) completed the second tranche of its non-brokered private placement, raising C$100,000 in gross proceeds, according to a company statement.

The Toronto Stock Exchange requires shareholder approval for the warrants before they become exercisable. The company will seek this approval no later than its next Annual

Appili Therapeutics Announces Closing of Second Tranche of Non-Brokered Private Placement

Wed, 18 Feb 2026 07:19:00 -0400

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES

HALIFAX, Nova Scotia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, is pleased to announce that it has closed the second tranche of its previously announced non-brokered private placement for aggregate gross proceeds of C$100,000 (the “Private Placement”).

The Private Placement consisted of the issuance and sale of 4,000,000 units of the Company (the “Units”) at a

Appili Therapeutics Announces Closing of Second Tranche of Non-Brokered Private Placement

Wed, 18 Feb 2026 07:19:00 -0400

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES

The Private Placement consisted of the issuance and sale of 4,000,000 units of the Company (the “Units”) at a

Appili Therapeutics Announces Closing of Second Tranche of Non-Brokered Private Placement

Wed, 18 Feb 2026 07:19:00 -0400

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES

The Private Placement consisted of the issuance and sale of 4,000,000 units of the Company (the “Units”) at a

Appili Therapeutics Announces Closing of Second Tranche of Non-Brokered Private Placement

Wed, 18 Feb 2026 07:19:00 -0400

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES

The Private Placement consisted of the issuance and sale of 4,000,000 units of the Company (the “Units”) at a